Daily Roundup | Bristol's Split IPF Result & RYZ101's Phase 3 Win

<p>Monday, October 12, 2026 edition, released Tuesday, October 13, 2026. News checked through October 13, 2026; no material updates to the stories below were found.</p><p><br /></p><p>Bristol's admilparant met its Phase 3 lung-function endpoint at the lower dose, while the higher dose missed significance in idiopathic pulmonary fibrosis. Its acquired RYZ101 program also delivered a Phase 3 win in neuroendocrine tumors after lutetium therapy, with benefit size still undisclosed. Mirum's LIVMARLI (maralixibat) reduced childhood itch in EXPAND, while the roundup covers First Tracks' ANB033 in celiac disease, Sebela's tegoprazan in reflux, Zenas' obexelimab in IgG4-related disease, Claris' eye-drop data and Ascelia's Orviglance regulatory path.</p><p><br /></p><p>Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.</p>